ArticleFrontiers in microbiology2026
Macrolide resistance trajectories across three
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Macrolide resistance in Methods: We performed stepwise erythromycin (ERY) induction using three clinical macrolide-susceptible parental isolates representing clinically relevant genetic backgrounds. Resistance-associated variants were tracked by whole-genome sequencing together with phenotypic readouts, including antimicrobial susceptibility testing, growth and biofilm assays, and ELISA-based measurements of selected virulence- and metabolism-associated factors. Results: ERY minimum inhibitory concentration (MIC) trajectories diverged across genetic backgrounds. B19068 and B181 reached high-level resistance and exhibited a 23S rRNA G2046A substitution in the consensus sequence, whereas B197 followed a lower-MIC trajectory and accumulated variants in efflux-associated loci. Whole-genome sequencing further revealed genomic alterations across genetic backgrounds, including structural variation in a subset of isolates, indicating that serial passaging under antibiotic exposure can be accompanied by genomic alterations beyond candidate resistance loci. Antibiotic-exposed lineages also displayed differences in growth and biofilm formation across genetic backgrounds, and ELISA readouts (PT, FHA, LPS, DHFS, and DHFR) differed across backgrounds under the Conclusion: Under a controlled induction regimen, three representative clinical genomic backgrounds exhibited divergent macrolide-resistance trajectories and accompanying phenotypic differences. These observations are consistent with background-linked differences in resistance evolution and provide a basis for future validation in replicated evolution experiments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.